🎉 M&A multiples are live!
Check it out!

Castle Biosciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Castle Biosciences and other public comps.

See Castle Biosciences Valuation Multiples

Castle Biosciences Overview

About Castle Biosciences

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.


Founded

2007

HQ

United States of America
Employees

610

Financials

LTM Revenue $322M

LTM EBITDA $62.0M

EV

$520M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Castle Biosciences Financials

Castle Biosciences has a last 12-month revenue of $322M and a last 12-month EBITDA of $62.0M.

In the most recent fiscal year, Castle Biosciences achieved revenue of $220M and an EBITDA of -$45.0M.

Castle Biosciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Castle Biosciences valuation multiples based on analyst estimates

Castle Biosciences P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $137M $220M $327M $322M XXX
Gross Profit $78.3M $105M $175M XXX XXX
Gross Margin 57% 48% 53% XXX XXX
EBITDA -$58.3M -$45.0M $71.0M $62.0M XXX
EBITDA Margin -43% -20% 22% 19% XXX
Net Profit -$31.3M -$67.1M -$57.5M XXX XXX
Net Margin -23% -31% -18% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

Castle Biosciences Stock Performance

As of February 10, 2025, Castle Biosciences's stock price is $28.

Castle Biosciences has current market cap of $773M, and EV of $520M.

See Castle Biosciences trading valuation data

Castle Biosciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$520M $773M XXX XXX XXX XXX $0.15

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Castle Biosciences Valuation Multiples

As of February 10, 2025, Castle Biosciences has market cap of $773M and EV of $520M.

Castle Biosciences's trades at 1.6x LTM EV/Revenue multiple, and 8.4x LTM EBITDA.

Analysts estimate Castle Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Castle Biosciences and 10K+ public comps

Castle Biosciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $520M XXX XXX XXX
EV/Revenue 1.6x XXX XXX XXX
EV/EBITDA 7.3x XXX XXX XXX
P/E 68.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 12.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Castle Biosciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Castle Biosciences Valuation Multiples

Castle Biosciences's NTM/LTM revenue growth is -14%

Castle Biosciences's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.4M for the same period.

Over next 12 months, Castle Biosciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Castle Biosciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Castle Biosciences and other 10K+ public comps

Castle Biosciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 49% XXX XXX XXX XXX
EBITDA Margin 22% XXX XXX XXX XXX
EBITDA Growth -258% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 8% XXX XXX XXX XXX
Revenue per Employee $0.4M XXX XXX XXX XXX
Opex per Employee $0.4M XXX XXX XXX XXX
S&M Expenses to Revenue 52% XXX XXX XXX XXX
G&A Expenses to Revenue 30% XXX XXX XXX XXX
R&D Expenses to Revenue 24% XXX XXX XXX XXX
Opex to Revenue 110% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Castle Biosciences Public Comps

See valuation multiples for Castle Biosciences public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
EZZ Life Science XXX XXX XXX XXX XXX XXX
ToolGen XXX XXX XXX XXX XXX XXX
4basebio XXX XXX XXX XXX XXX XXX
Genus XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Castle Biosciences M&A and Investment Activity

Castle Biosciences acquired  XXX companies to date.

Last acquisition by Castle Biosciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Castle Biosciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Castle Biosciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Castle Biosciences

When was Castle Biosciences founded? Castle Biosciences was founded in 2007.
Where is Castle Biosciences headquartered? Castle Biosciences is headquartered in United States of America.
How many employees does Castle Biosciences have? As of today, Castle Biosciences has 610 employees.
Who is the CEO of Castle Biosciences? Castle Biosciences's CEO is Mr. Derek J. Maetzold.
Is Castle Biosciences publicy listed? Yes, Castle Biosciences is a public company listed on NAS.
What is the stock symbol of Castle Biosciences? Castle Biosciences trades under CSTL ticker.
When did Castle Biosciences go public? Castle Biosciences went public in 2019.
Who are competitors of Castle Biosciences? Similar companies to Castle Biosciences include e.g. EZZ Life Science, ToolGen, 4basebio, Genus.
What is the current market cap of Castle Biosciences? Castle Biosciences's current market cap is $773M
What is the current revenue of Castle Biosciences? Castle Biosciences's last 12-month revenue is $322M.
What is the current EBITDA of Castle Biosciences? Castle Biosciences's last 12-month EBITDA is $62.0M.
What is the current EV/Revenue multiple of Castle Biosciences? Current revenue multiple of Castle Biosciences is 1.6x.
What is the current EV/EBITDA multiple of Castle Biosciences? Current EBITDA multiple of Castle Biosciences is 8.4x.
What is the current revenue growth of Castle Biosciences? Castle Biosciences revenue growth between 2023 and 2024 was 49%.
Is Castle Biosciences profitable? Yes, Castle Biosciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.